-

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2025, at 3:45 p.m. PT.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at:

https://jpmorgan.metameetings.net/events/healthcare25/sessions/58328-organon/webcast?gpu_only=true&kiosk=true

About Organon

Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers more than 60 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators who look to commercialize their products by leveraging Organon’s scale and agile presence in fast growing international markets.

Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.

Contacts

Media Contacts:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Organon & Co.

NYSE:OGN
Details
Headquarters: Jersey City, New Jersey, USA
CEO: Joseph Morrissey
Employees: 10,000
Organization: PUB

Release Summary
Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th
Release Versions

Contacts

Media Contacts:

Karissa Peer
(614) 314-8094

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Social Media Profiles
More News From Organon & Co.

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST....

Organon Completes Divestiture of JADA® System to Laborie

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp....

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs....
Back to Newsroom